Table 2 Association of lncRNA WEE2-AS1 expression with clinical pathological characteristics by logistic regression
From: LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma
Characteristics | Total (N) | Odds Ratio (OR) | P |
|---|---|---|---|
Age ( < = 60 vs. >60) | 670 | 0.92(0.86–0.98) | 0.01 |
Gender (Female vs. Male) | 670 | 0.96(0.90–1.01) | 0.141 |
Race (Asian vs. Black or African American & White) | 658 | 1.08(0.89–1.28) | 0.396 |
Primary therapy outcome (CR vs. PD & SD & PR) | 444 | 0.95(0.87–1.03) | 0.245 |
WHO grade (G2 vs. G3 & G4) | 613 | 0.84(0.78–0.90) | < 0.001 |
Histological type (Astrocytoma & Oligoastrocytoma & Oligodendroglioma vs. Glioblastoma) | 670 | 0.80(0.75–0.85) | < 0.001 |
IDH status (WT vs. Mut) | 661 | 1.24(1.17–1.33) | < 0.001 |
1p/19q codeletion (Codel vs. Non-codel) | 664 | 0.65(0.58–0.72) | < 0.001 |
EGFR status (WT vs. Mut) | 656 | 0.86(0.79–0.93) | < 0.001 |
PIK3CA status (WT vs. Mut) | 656 | 1.02(0.92–1.15) | 0.703 |